Scarica l'app Stockscreener
0.5215
3.70%
0.0186
Dopo l'orario di chiusura:
.52
-0.0015
-0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
Form 8K Humacyte Inc For: 28 September By Investing.com - Investing.com Nigeria
Humacyte Director D. Scott Coward Files Form 3 Reporting No Beneficial Ownership - kalkinemedia.com
Two new directors join Humacyte (HUMA), one on the audit committee and one on the commercial committee. - Stock Titan
Humacyte, Inc.Common Stock (NQ: HUMA - The Chronicle-Journal
Humacyte, Inc. Announces Board and Committees Appointments - marketscreener.com
Humacyte Adds Scott Coward and Paul Kuznik to Board Ahead of Dialysis Launch - citybiz
A new board member brings more than 30 years in vascular care to Humacyte - Stock Titan
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Humacyte, Inc. (HUMA) Stock Analysis: Unpacking a 221.68% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Humacyte (HUMA) Extends Rally with +0.88% Gain 2026-09-17Gap and Go - careplusvn.com
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte (NASDAQ: HUMA) director now holds 50,000 shares - Stock Titan
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Humacyte CEO to speak in New York on Sept. 16 - Stock Titan
Humacyte ATEV shows superiority in Phase 3 V012 study - scanx.trade
Hospitals can keep an emergency blood-vessel graft for 36 months, up from 18 - Stock Titan
Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months - Yahoo Finance
HC Wainwright raises Humacyte price target to $4 - scanx.trade
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc. Warrant (HUMAW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Humacyte Inc. Warrant (HUMAW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Humacyte Inc. Warrant (HUMAW) Peer Comparison – Compare with Others - Value Research
Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq - Stock Titan
Humacyte plans November FDA filing for dialysis access use By Investing.com - Investing.com Nigeria
Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data - Quiver Quantitative
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds. - Pluang
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo
Humacyte (HUMA) Shares: Records a 7.28% Decrease to $0.68 on the Day; Next Session - vinanet.vn
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.25 - Moomoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Australia
Humacyte publishes Phase 3 trial results in Lancet journal - Investing.com
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
MSN Money - MSN
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte Q2 Revenue Rises to $0.4 Million as Net Loss Narrows - Moomoo
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... - Yahoo Finance Australia
Humacyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Humacyte, Inc. Q2 2026: Revenue $406K, EPS $(0.16) — 10-Q Summary - TradingView
Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk - Stock Titan
HUMA Q2 FY2026 earnings call - finance.biggo.com
Sutro Biopharma, Humacyte, CoreWeave - TradingView
Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results - MarketBeat
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):